Hospira Spins Off With $4.2 Bil. Market Cap; Abbokinase Stays With Abbott

Abbott initially pegged Abbokinase as one of its hospital-based products to be divested with Hospira, but later decided the drug had a more strategic fit with the rest of its Rx portfolio.